Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A European collaborative initiative to systematically map cancer risk by migration background: the Cancer RADAR project.

International journal for equity in health·2026
Same author

Population-Based First Estimates of the Effect of HPV Vaccination in Three Italian Areas Covered by Organised Cervical Screening.

International journal of cancer·2026
Same author

From evidence to action: the IARC's role in strengthening cancer prevention and early detection.

Journal of the National Cancer Institute. Monographs·2026
Same author

Oncogenic infections: targets highly amenable to cancer prevention.

Journal of the National Cancer Institute. Monographs·2026
Same author

Systematic review and meta-analysis of cervico-vaginal high-risk human papillomavirus prevalence in India prior to nationwide human papillomavirus vaccination.

Archives of public health = Archives belges de sante publique·2026
Same author

Correction to "Predicting cohort-specific cervical cancer incidence from population-based surveys of human papilloma virus prevalence: a worldwide study".

American journal of epidemiology·2026

Related Experiment Video

Updated: Feb 23, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.0K

Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.

Iacopo Baussano1, Fulvio Lazzarato1,2, Guglielmo Ronco3

  • 1International Agency for Research on Cancer, Lyon, France.

The Journal of Infectious Diseases
|September 2, 2017
PubMed
Summary

Human papillomavirus (HPV) vaccination effectiveness varies by type, with HPV45 benefiting more from herd protection than HPV16. Achieving high coverage is crucial for eliminating HPV infections.

Keywords:
HPV vaccinationcervical cancer controlcross-protectionherd effect

More Related Videos

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.6K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.4K

Related Experiment Videos

Last Updated: Feb 23, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.0K
A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.6K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.4K

Area of Science:

  • Epidemiology
  • Vaccinology
  • Mathematical Modeling

Background:

  • Human papillomavirus (HPV) vaccination uptake remains suboptimal in many high-risk populations.
  • Current HPV16/18 vaccines provide cross-protection against other HPV types, including HPV45.
  • Both direct vaccine efficacy and indirect herd protection are key to overall vaccination effectiveness.

Purpose of the Study:

  • To estimate the vaccination effectiveness against HPV16 and HPV45 infections using a dynamic transmission model.
  • To assess the impact of varying cross-protection levels for HPV45 on vaccination effectiveness.
  • To evaluate the influence of vaccination coverage and strategy (gender-specific vs. gender-neutral) on infection reduction.

Main Methods:

  • A dynamic transmission model was employed for the study.
  • The model was calibrated using cervical screening data from Italy.
  • Vaccination effectiveness was estimated for HPV16 and HPV45, considering different cross-protection scenarios for HPV45.

Main Results:

  • HPV45 demonstrated stronger vaccine effectiveness and herd protection compared to HPV16 due to a smaller basic reproductive number.
  • In girls-only vaccination programs at 70% coverage, HPV45 infection prevalence reduction was higher (99%) than for HPV16 (83%), largely due to superior herd protection.
  • Gender-neutral vaccination at 40% coverage showed substantial herd protection for HPV45 (54%) versus HPV16 (28%).
  • Even 50% cross-protection against HPV45 significantly reduced infection prevalence (≥94%) at ≥80% vaccination coverage.

Conclusions:

  • The characteristics of specific high-risk HPV types significantly impact herd protection dynamics.
  • Vaccination coverage and cross-protection levels are critical determinants for reducing or eliminating HPV infections.
  • HPV16 infections and associated cancers present the greatest challenge for elimination via current vaccination strategies.